TauRx Therapeutics Management

TauRx Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments and diagnostics for Alzheimer's disease and other neurodegenerative disorders. The company is a leader in tau-based research, focusing on the discovery of tau aggregation inhibitors that target the pathological misfolding of tau proteins in the brain. Their lead candidate, hydromethylthionine mesylate (HMTM), has undergone extensive Phase 3 clinical testing and aims to be a first-in-class disease-modifying therapy. Based in Singapore with significant operations in Aberdeen, Scotland, TauRx leverages decades of academic research to address the global challenge of dementia. The company's unique approach focuses on slowing the progression of cognitive decline by preventing the formation of toxic tau tangles.